TY  - GEN 
AU  - Rand, Kim
AU  - Ramos-Goñi, Juan Manuel
AU  - Akmaz, Bülent
AU  - Solé-Feu, Laia
AU  - Armario Hita, José Carlos
A4  - Cirugía
A4  - Medicina
PY  - 2024
SN  - 2190-9172
SN  - 2193-8210
UR  - http://hdl.handle.net/10498/32321
AB  - Introduction: Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over the 16-week SOLOs and ADvocate trials. However, AD is a chronic and...
LA  - eng
PB  - Adis
KW  - Atopic dermatitis
KW  - Dupilumab
KW  - Eczema
KW  - Lebrikizumab
KW  - Matching-adjusted indirect comparison
TI  - Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
DO  - https://doi.org/10.1007/S13555-023-01058-Z
ER  -